文献速递药物不良反应与药物警戒

评估COVID-19疫苗安全性:入门指南

Assessing the Safety of COVID-19 Vaccines: A Primer.
PubMed 文献 · Drug Saf · 2020-09-30

本文概述了COVID-19疫苗快速部署背景下上市后安全性监测的挑战与沟通需求,强调需建立稳健的药物警戒和主动监测系统,并整合监测系统、行政数据和特殊关注不良事件病例定义等工具,但需投资与协作。

要点

  • COVID-19疫苗快速开发对上市后安全性监测和沟通带来挑战。
  • 需建立稳健的药物警戒和主动监测系统以支持疫苗快速部署。
  • 部分国家缺乏监测能力,需依赖他国数据,整合工具需投资与协作。

核心结论

  • 现代疫苗安全性评估工具可用于COVID-19疫苗部署,但有效整合需投资与协作。

研究设计与样本

  • 本文为高层面概述,未报告系统检索方法或样本量。

主要发现

  • 监测系统、行政数据和特殊关注不良事件病例定义等工具已存在,可用于COVID-19疫苗安全性评估。

临床怎么用

  • 临床药学人员应关注COVID-19疫苗上市后安全性监测数据,并参与不良事件报告与沟通。

局限性

  • 本文为高层面概述,未提供具体研究数据或系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines against COVID-19 are being developed at speeds not previously achieved. With this unprecedented effort comes challenges for post-marketing safety monitoring and challenges for vaccine safety communication. To deploy these new vaccines fast across diverse populations, it is vital that robust pharmacovigilance and active surveillance systems are in place. Not all countries have the capability or resources to undertake adequate surveillance and will rely on data from those who can. The tools exist to assess COVID-19 vaccines as they are deployed such as surveillance systems, administrative data and case definitions for adverse events of special interest. However, stitching these all together and using them effectively requires investment and collaboration. This paper provides a high-level overview of some of the facets of modern vaccine safety assessment and how they are, or can be, applied to COVID-19 vaccines.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2020. PMID: 32997318. doi:10.1007/s40264-020-01002-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。